Dr Reddy's Laboratories launches Regadenoson injection in US market

The injection is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. In a separate filing, Dr Reddy's said it has issued a Form 483 with one observation by the USFDA after a routine GMP inspection at its API manufacturing facility (CTO 1) in Bollaram, Hyderabad.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news